Charles River Laboratories International, Inc. (CRL)

230,09 -2,25 (-0,97%) Alla chiusura: 04:00PM EDT

Charles River Laboratories International, Inc.

251 Ballardvale Street
Wilmington, MA 01887
United States
781 222 6000
https://www.criver.com

Settore/i: Healthcare
Settore: Diagnostics & Research
Impiegati a tempo pieno: 20.400

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Ms. Flavia H. Pease	Corporate Executive VP & CFO	1,66M	N/D	1973
Ms. Birgit Girshick	Corporate Executive VP & COO	1,28M	464,88k	1970
Mr. Joseph W. LaPlume	Corporate Executive Vice President of Corporate Development & Strategy	928,36k	262,98k	1974
Mr. William D. Barbo	Corporate Executive Vice President of Community Relations	1M	399,92k	1961
Mr. Michael Gunnar Knell	Corporate Senior VP & Chief Accounting Officer	N/D	N/D	1977
Prof. Julie Frearson Ph.D.	Corporate Senior VP & Chief Scientific Officer	N/D	N/D	N/D
Mr. Mark Mintz	Corporate Senior VP & Chief Information Officer	N/D	N/D	N/D
Todd Spencer	Corporate Vice President of Investor Relations	N/D	N/D	N/D
Mr. Matthew L. Daniel	Corporate Senior VP, General Counsel, Corporate Secretary & Chief Compliance Officer	N/D	N/D	N/D
Ms. Amy Cianciaruso	Corporate Vice President & Chief Communications Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Charles River Laboratories International, Inc. al 1 aprile 2024 è 8. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 6; diritti degli azionisti: 8; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.